Premier Investment Firm Adds Physician-Scientist and Drug Developer to Further Advance Its Therapeutics and Life Sciences Strategy

Breyer Capital, a premier venture capital investor focused on backing high-impact entrepreneurs, today announced the appointment of Dr. Bret Bostwick as Venture Advisor. Dr. Bostwick will work closely with Dr. Morgan Cheatham, Partner and Head of Healthcare & Life Sciences at Breyer Capital, who leads the firm’s investment strategy in the sector, and with Founder and CEO Jim Breyer. Together, they will continue to build an integrated healthcare and life sciences investment platform spanning drug discovery through care delivery. In this role, Dr. Bostwick will strengthen investment, incubation, and portfolio efforts across therapeutics and life sciences, contributing translational and clinical judgment to Breyer Capital’s healthcare and life sciences practice.

Dr. Bostwick is a physician-scientist and drug developer with senior leadership experience across translational medicine, drug discovery, and clinical development. Building on Breyer Capital’s healthcare and life sciences practice, his perspective adds translational and clinical rigor to how the firm evaluates early science and supports companies as programs progress from discovery into development.

“Partnering with Dr. Bret Bostwick is an exciting inflection point for our healthcare and life sciences practice,” said Dr. Morgan Cheatham. “His depth in evaluating groundbreaking science through a translational and clinical lens will meaningfully shape how we assess opportunities and support companies as they move from discovery to the clinic.”

Before joining the firm, Dr. Bostwick served as Senior Medical Director at Alnylam Pharmaceuticals, where he co-invented multiple CNS-targeted RNAi therapeutics and led translational work supporting mivelsiran, the first siRNA to demonstrate gene silencing in the human brain. Previously, he was Chief of Pediatric Genetics at Texas Children’s Hospital and held a faculty appointment at Baylor College of Medicine as a clinical medical geneticist. Currently, he leads Translational Medicine Solutions, an advisory firm at the intersection of healthcare, technology, and venture capital.

“We’re thrilled to welcome Dr. Bret Bostwick to the team,” said Breyer Capital Founder and CEO Jim Breyer. "His experience across academic medicine, biotechnology, and venture investing gives him a rare perspective on how scientific ideas become actionable programs and companies. He will play an important role in sharpening our work in targeted therapeutics and across the broader life sciences landscape.”

Dr. Bostwick joins Sam Palmisano (former CEO and Chairman of IBM) among others, as part of Breyer Capital’s Venture Advisor group.

“Breyer Capital is at the forefront of driving meaningful impact in breakthrough technologies,” said Dr. Bostwick. “What energizes me most is partnering with exceptional founders as scientific insight becomes a translational path toward real-world impact. I’m thrilled to join Breyer Capital and look forward to helping scale companies across the firm’s impressive portfolio.”

About Breyer Capital

Breyer Capital is a premier venture capital firm focused on catalyzing high-impact entrepreneurs. Founded by Jim Breyer in 2006, the firm makes long-term, idea-driven investments across artificial intelligence, healthcare, life sciences, enterprise, consumer, and financial technologies. Breyer Capital partners closely with founders building transformative companies anchored in technological and scientific innovation, and its portfolio includes category-defining companies such as OpenEvidence, Facebook, Meta, Spotify, and Circle, among others. For more information, please visit www.breyercapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251219213610/en/